厄洛替尼单药一线治疗非小细胞肺癌的研究进展

高效低毒的分子靶向治疗药物厄洛替尼,在非小细胞肺癌(NSCLC)的二、三线治疗以及序贯和维持治疗中,已经显示出其能够使患者临床获益.厄洛替尼单药为晚期NSCLC的一线治疗新的选择方案.本文就其在老年、体力状态较差、不吸烟以及存在表皮生长因子(EGFR)敏感性突变或K-ras耐药突变的NSCLC患者中的应用作一综述.

Advanced in search for erlotinib as the first-line monotherapy for non-small cell lung cancer

The molecular targeted therapy drug erlotinib,with property of high-performance and low toxicity,has been shown to benefit the survival of patients in the second and third-line treatment,as well as sequential and maintenance therapy of non-small-cell lung cancer (NSCLC).Recently,the results of clinical trials about erlotinib as first -line monotherapy for the selective patients have provided new options for the first-line treatment ofadvanced NSCLC.In this paper,we make a review about progress of recent clinical trials of elotinib as first-line monotherapy for the elder patients,patients with poor physical status,non-smoking patients,epidermal growth factor receptor(EGFR)sensitive mutations or K-ras resistant mutation.